← Leaderboards
Elizabeth Trask Montgomery
Research Triangle Institute
$5,464,924
Attributed
$5,464,924
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,464,924 · 3
By mechanism
R01$5,464,924 · 3
Top collaborators
No co-investigators on record.
Most similar at Research Triangle Institute
Same institution · by research overlap
- Li-Tzy T Wu$8,276,349
- Wendee M Wechsberg$36,676,071
- Frank I Carroll$18,291,450
- Abhik Das$191,149,327
- Marie G Gantz$56,295,649
Research focus
Africa South Of The SaharaOralWomanAids PreventionIntramuscular InjectionsNovel StrategiesDoseSouth AfricaInjectablePreferenceProduct DevelopmentInterviewEffectivenessUptakePublic HealthAgedFutureYoung ManFormulationAttitudeFoundationsPre-Exposure ProphylaxisRegimenQualitative Research
Grant awards (9)
Reaching the last 20%: a targeted HIV self-test secondary distribution intervention to engage high-risk men in Kenya$556,637
R01 · FY2025 · MH · contact PI
Men's Acceptability of Long-acting HIV prevention methods in South Africa$632,780
R01 · FY2023 · MH · contact PI
Men's Acceptability of Long-acting HIV prevention methods in South Africa$486,214
R01 · FY2023 · MH · contact PI
Men's Acceptability of Long-acting HIV prevention methods in South Africa$621,526
R01 · FY2022 · MH · contact PI
Men's Acceptability of Long-acting HIV prevention methods in South Africa$681,653
R01 · FY2021 · MH · contact PI
Men's Acceptability of Long-acting HIV prevention methods in South Africa$717,504
R01 · FY2020 · MH · contact PI
End-user research to optimize adherence to injectable HIV prevention approaches$584,340
R01 · FY2017 · MH · contact PI
End-user research to optimize adherence to injectable HIV prevention approaches$570,514
R01 · FY2016 · MH · contact PI
End-user research to optimize adherence to injectable HIV prevention approaches$613,756
R01 · FY2015 · MH · contact PI